[go: up one dir, main page]

MA39750B1 - Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2 - Google Patents

Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2

Info

Publication number
MA39750B1
MA39750B1 MA39750A MA39750A MA39750B1 MA 39750 B1 MA39750 B1 MA 39750B1 MA 39750 A MA39750 A MA 39750A MA 39750 A MA39750 A MA 39750A MA 39750 B1 MA39750 B1 MA 39750B1
Authority
MA
Morocco
Prior art keywords
modulators
indol
aza
acetic acid
derivatives
Prior art date
Application number
MA39750A
Other languages
English (en)
Other versions
MA39750A (fr
Inventor
Christoph Boss
Hamed Aissaoui
Patrick Bouis
Julien Hazemann
Romain Siegrist
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA39750A publication Critical patent/MA39750A/fr
Publication of MA39750B1 publication Critical patent/MA39750B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des dérivés d'acide aza-indol-acétique de formule (i), dans laquelle r1 et r2 sont tels que définis dans la description, et leur utilisation comme modulateurs des récepteurs des prostaglandines, plus particulièrement comme modulateurs des récepteurs de la prostaglandine d2, dans le traitement de divers troubles et maladies à médiation par des prostaglandines, ainsi que des compositions pharmaceutiques contenant lesdits composés et des procédés pour leur préparation
MA39750A 2014-03-17 2015-03-16 Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2 MA39750B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2014059883 2014-03-17
PCT/IB2015/051895 WO2015140684A1 (fr) 2014-03-17 2015-03-16 Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
EP15714030.2A EP3119779B1 (fr) 2014-03-17 2015-03-16 Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2

Publications (2)

Publication Number Publication Date
MA39750A MA39750A (fr) 2017-01-25
MA39750B1 true MA39750B1 (fr) 2018-12-31

Family

ID=52808086

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39750A MA39750B1 (fr) 2014-03-17 2015-03-16 Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2

Country Status (31)

Country Link
US (2) US9879006B2 (fr)
EP (1) EP3119779B1 (fr)
JP (1) JP6152489B2 (fr)
KR (1) KR101864060B1 (fr)
CN (1) CN106103435B (fr)
AR (1) AR099767A1 (fr)
AU (1) AU2015233029B2 (fr)
BR (1) BR112016021471B1 (fr)
CA (1) CA2939892C (fr)
CL (1) CL2016002321A1 (fr)
CY (1) CY1120744T1 (fr)
DK (1) DK3119779T3 (fr)
EA (1) EA030159B1 (fr)
ES (1) ES2687279T3 (fr)
HR (1) HRP20181555T1 (fr)
HU (1) HUE039614T2 (fr)
IL (1) IL247705B (fr)
LT (1) LT3119779T (fr)
MA (1) MA39750B1 (fr)
MX (2) MX368179B (fr)
MY (1) MY179356A (fr)
PE (1) PE20161177A1 (fr)
PH (1) PH12016501764B1 (fr)
PL (1) PL3119779T3 (fr)
PT (1) PT3119779T (fr)
RS (1) RS57867B1 (fr)
SG (1) SG11201607708RA (fr)
SI (1) SI3119779T1 (fr)
TW (1) TWI649321B (fr)
UA (1) UA117780C2 (fr)
WO (1) WO2015140684A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY179356A (en) * 2014-03-17 2020-11-05 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2015140701A1 (fr) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
CA2993893A1 (fr) * 2015-09-15 2017-03-23 Idorsia Pharmaceuticals Ltd Formes cristallines
KR102480088B1 (ko) * 2016-03-17 2022-12-23 삼성디스플레이 주식회사 양자점 발광 소자

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808608A (en) 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
DE3631824A1 (de) 1986-02-21 1988-03-31 Bayer Ag Cycloalkano(1.2-b)indol-sulfonamide
GB8924392D0 (en) 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
WO2001078697A2 (fr) 2000-04-12 2001-10-25 Merck Frosst Canada & Co. Procede et compositions destines au traitement d'etats allergiques faisant appel a des antagonistes du recepteur pgd2
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
AU2002302248B2 (en) 2001-05-23 2008-03-06 Merck Frosst Canada Ltd. Dihydropyrrolo[1,2-A]indole and tetrahydropyrido[1,2-A]-indole derivatives as prostaglandin D2 receptor antagonists
CN100500654C (zh) 2001-12-14 2009-06-17 赞塔里斯有限公司 作为g-蛋白偶联受体(gpcr)的配体的四氢咔唑衍生物
US6837970B2 (en) 2001-12-18 2005-01-04 Kimberly-Clark Worldwide, Inc. Wood pulp fiber morphology modifications through thermal drying
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
AU2003231513A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Pgd2 receptor antagonist
US7534897B2 (en) 2002-05-16 2009-05-19 Shionogi & Co., Ltd. Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
GB2388540A (en) 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
JP4332151B2 (ja) 2002-10-30 2009-09-16 メルク フロスト カナダ リミテツド ピリドピロリジンおよびピリドインドリジン誘導体
WO2004078719A1 (fr) 2003-03-06 2004-09-16 Ono Pharmaceutical Co., Ltd. Composes a base de derives d'indole et medicaments contenant lesdits composes en tant que principe actif
CA2526013A1 (fr) 2003-05-20 2004-12-02 Merck Frosst Canada Ltd. Fluoro-methanesulfonyl- cycloalkanoindoles substitues et leur utilisation en tant qu'antagonistes de prostaglandine d2
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
EP1638967A2 (fr) 2003-06-12 2006-03-29 Merck Frosst Canada Ltd. Cycloalkanepyrrolopyridines utilisees comme antagonistes du recepteur dp
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
WO2005033099A2 (fr) 2003-10-03 2005-04-14 Glenmark Pharmaceuticals Ltd. Nouveaux inhibiteurs de dipeptidylpeptidase iv, leurs procedes de preparation et compositions les contenant
RU2006109108A (ru) 2003-10-14 2007-11-20 Оксаген Лимитед (GB) Соединения, обладающие активностью антагонистов crth2 рецепторов
WO2005040112A1 (fr) 2003-10-14 2005-05-06 Oxagen Limited Composes a activite antagoniste de pgd2
GB2407318A (en) 2003-10-23 2005-04-27 Oxagen Ltd Substituted Indol-3-yl acetic acid derivatives
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
NZ548396A (en) 2004-01-31 2010-06-25 Actimis Pharmaceuticals Inc Imidazo[1,2-C]pyrimidinylacetic acid derivatives
WO2005095397A1 (fr) 2004-03-11 2005-10-13 Actelion Pharmaceuticals Ltd Derives de tetrahydropyridoindole
CA2558545C (fr) 2004-03-11 2012-10-16 Actelion Pharmaceuticals Ltd Derives d'acide indol-1-yl-acetique
US20050234030A1 (en) 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
GB0412914D0 (en) 2004-06-10 2004-07-14 Oxagen Ltd Compounds
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
KR20070089908A (ko) 2004-09-21 2007-09-04 아더시스 인코포레이티드 Ｃｒｔｈ２ 수용체 길항작용을 나타내는 인돌 아세트산 및이의 용도
BRPI0515522A (pt) 2004-09-21 2008-07-29 Athersys Inc composto, composição farmacêutica. métodos de inibir a ligação de ligandos endógenos ao receptor crth-2 em uma célula, de tratar, melhorar ou prevenir um distúrbio responsivo à inibição da ligação de ligandos endógenos ao receptor crth-2 em um animal e de preparar um composto, e, kit
GB0427381D0 (en) 2004-12-14 2005-01-19 Novartis Ag Organic compounds
PT1833791E (pt) 2004-12-27 2011-10-19 Actelion Pharmaceuticals Ltd Derivados de 2,3,4,9-tetra-hidro-1h-carbazol como antgonistas do receptor crth2
DOP2006000016A (es) 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
GB2422830A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
GB2422831A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
GB2422829A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
JP5024039B2 (ja) 2005-02-25 2012-09-12 小野薬品工業株式会社 インドール化合物およびその用途
GB0504150D0 (en) 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
CN101300259B (zh) 2005-05-24 2013-08-28 默克雪兰诺有限公司 作为crth2调节剂的三环螺衍生物
GB0512944D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Indolizine compounds
US7842692B2 (en) 2005-07-22 2010-11-30 Shionogi & Co., Ltd. Azaindole derivative having PGD2 receptor antagonistic activity
EP1916245B1 (fr) 2005-07-22 2011-10-26 Shionogi & Co., Ltd. Dérivé d'indole ayant une activité antagoniste vis-à-vis du récepteur de la pgd2
CA2618550C (fr) 2005-08-12 2013-12-17 Merck Frosst Canada Ltd. Derives d'indole en tant qu'antagonistes du recepteur crth2
WO2007022501A2 (fr) 2005-08-18 2007-02-22 Microbia, Inc. Composes indoles utiles
EP1932839A4 (fr) 2005-09-06 2014-09-10 Shionogi & Co Dérivé d acide indolécarboxylate ayant une activité à effet antagoniste du récepteur pgd2
GB0518783D0 (en) 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
GB0521275D0 (en) 2005-10-19 2005-11-30 Argenta Discovery Ltd 3-Aminoindole compounds
GB0525141D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525144D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) 2005-12-13 2006-01-18 Novartis Ag Organic compounds
GB0605743D0 (en) 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
CN102558021A (zh) 2006-05-26 2012-07-11 阿斯利康(瑞典)有限公司 联芳基或芳基-杂芳基取代的吲哚类化合物
GB0611695D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
WO2008012511A1 (fr) 2006-07-22 2008-01-31 Oxagen Limited Composés présentant une activité d'antagonistes crth2
DE602007010010D1 (de) 2006-07-25 2010-12-02 Sanofi Aventis 2-phenylindole als antagonisten des prostaglandin-d2-rezeptors
SI2051962T1 (sl) 2006-08-07 2012-02-29 Actelion Pharmaceuticals Ltd Derivati (3-amino-1,2,3,4-tetrahidro-9h-karbazol-9-il)-ocetne kisline
EP2094266A1 (fr) 2006-12-21 2009-09-02 Argenta Discovery Limited Antagonistes de crth2
GB0625842D0 (en) 2006-12-22 2007-02-07 Argenta Discovery Ltd Indolizine derivatives
EP2136804A1 (fr) 2007-03-21 2009-12-30 Argenta Oral Therapeutics Limited Dérivés indolizine d'acide acétique utilisés comme antagonistes de crth2
GB0719485D0 (en) 2007-10-05 2007-11-14 Argenta Discovery Ltd Compounds
GB0719521D0 (en) 2007-10-05 2007-11-14 Argenta Discovery Ltd Compounds
WO2009049021A1 (fr) 2007-10-10 2009-04-16 Chemietek, Llc Composés hétérocycliques sous forme d'antagonistes du récepteur crth2
US20100280049A1 (en) 2007-11-06 2010-11-04 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
GB0722216D0 (en) 2007-11-13 2007-12-27 Oxagen Ltd Use of crth2 antagonist compounds
GB0722203D0 (en) 2007-11-13 2007-12-19 Oxagen Ltd Use of CRTH2 antagonist compounds
PL2327693T3 (pl) 2007-12-14 2012-11-30 Pulmagen Therapeutics Asthma Ltd Indole i ich zastosowanie terapeutyczne
BRPI0906786B1 (pt) 2008-01-18 2021-10-05 Atopix Therapeutics Limited Composto, processo para a preparação de um composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, e, produto
WO2009090399A1 (fr) 2008-01-18 2009-07-23 Argenta Discovery Limited Indoles actifs sur le récepteur crth2
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
US20100022613A1 (en) 2008-01-22 2010-01-28 Oxagen Limited Compounds Having CRTH2 Antagonist Activity
EP2240444A1 (fr) 2008-01-22 2010-10-20 Oxagen Limited Composés présentant une activité antagoniste de crth2
JP2011088826A (ja) 2008-01-31 2011-05-06 Astellas Pharma Inc 芳香族カルボン酸化合物
US20110112134A1 (en) 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
WO2010008864A2 (fr) 2008-06-24 2010-01-21 Amira Pharmaceuticals, Inc. Antagonistes de cycloalcane[b]indole de récepteurs de prostaglandine d2
ES2386948T3 (es) 2008-07-15 2012-09-07 F. Hoffmann-La Roche Ag Ácidos aminotetrahidroindazoloacéticos
CA2728311A1 (fr) 2008-07-15 2010-01-21 F. Hoffmann-La Roche Ag Acides aminotetrahydroindazoloacetiques
CA2737460C (fr) 2008-09-22 2016-12-20 Merck Frosst Canada Ltd. Derives d'indole utilisables en tant qu'antagonistes du recepteur crth2
WO2010031184A1 (fr) 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Dérivés d'azaindole comme antagonistes du récepteur crth2
EP2346865B1 (fr) 2008-09-22 2015-07-15 Merck Canada Inc. Dérivés d'indole comme antagonistes du récepteur crth2
US20110312945A1 (en) 2008-10-01 2011-12-22 James Jia Crth2 modulators
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
WO2010085820A2 (fr) 2009-01-26 2010-07-29 Amira Pharmaceuticals, Inc. Composés tricycliques en tant qu'antagonistes des récepteurs d2 de la prostaglandine
SI2401269T1 (sl) 2009-02-24 2014-04-30 Merck Sharp & Dohme Corp. Derivati indola kot crth2 receptorski antagonisti
WO2010142934A1 (fr) 2009-06-12 2010-12-16 Pulmagen Therapeutics (Asthma) Limited Dérivés d'indole en tant que ligands des récepteurs crth2
WO2011006936A1 (fr) 2009-07-15 2011-01-20 Merck Serono S.A. Dérivés spiro issus d'indole tricyclique comme modulateurs de crth2
WO2011014588A2 (fr) * 2009-07-31 2011-02-03 Amira Pharmaceuticals, Inc. Préparations dermiques d'antagonistes du récepteur dp2
WO2011055270A1 (fr) 2009-11-04 2011-05-12 Wyeth Llc Antagonistes des récepteurs crth2 à base d'indole
CN102791689B (zh) * 2010-03-22 2014-10-29 埃科特莱茵药品有限公司 3-（杂芳基-氨基）-1,2,3,4-四氢-9h-咔唑衍生物及其作为前列腺素d2受体调节剂的用途
US20110311483A1 (en) 2010-03-30 2011-12-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009134A1 (fr) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Modulateurs de crth2
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
SG193902A1 (en) 2011-04-14 2013-11-29 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
CN103450218B (zh) 2012-05-29 2015-12-23 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的吲哚类三并环衍生物
MY179356A (en) * 2014-03-17 2020-11-05 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2015140701A1 (fr) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
CA2993893A1 (fr) 2015-09-15 2017-03-23 Idorsia Pharmaceuticals Ltd Formes cristallines

Also Published As

Publication number Publication date
HRP20181555T1 (hr) 2018-11-30
AR099767A1 (es) 2016-08-17
JP2017507998A (ja) 2017-03-23
RS57867B1 (sr) 2018-12-31
CN106103435A (zh) 2016-11-09
PH12016501764A1 (en) 2017-02-06
AU2015233029B2 (en) 2018-11-29
EP3119779B1 (fr) 2018-07-11
PL3119779T3 (pl) 2019-01-31
CY1120744T1 (el) 2019-12-11
LT3119779T (lt) 2018-09-10
KR101864060B1 (ko) 2018-06-01
IL247705A0 (en) 2016-11-30
CN106103435B (zh) 2018-11-16
SG11201607708RA (en) 2016-10-28
MX2016011901A (es) 2016-12-05
NZ725150A (en) 2020-11-27
CA2939892C (fr) 2020-03-31
HUE039614T2 (hu) 2019-01-28
EP3119779A1 (fr) 2017-01-25
EA201691855A1 (ru) 2017-02-28
PT3119779T (pt) 2018-10-19
WO2015140684A1 (fr) 2015-09-24
BR112016021471A2 (pt) 2017-08-15
UA117780C2 (uk) 2018-09-25
TWI649321B (zh) 2019-02-01
BR112016021471A8 (pt) 2021-06-29
PH12016501764B1 (en) 2024-05-17
AU2015233029A1 (en) 2016-11-03
BR112016021471B1 (pt) 2022-10-11
CL2016002321A1 (es) 2017-05-12
MX2019011265A (es) 2019-12-19
DK3119779T3 (en) 2018-10-22
SI3119779T1 (sl) 2018-10-30
MX368179B (es) 2019-09-23
ES2687279T3 (es) 2018-10-24
TW201620908A (zh) 2016-06-16
US20170022196A1 (en) 2017-01-26
US9879006B2 (en) 2018-01-30
KR20160133554A (ko) 2016-11-22
IL247705B (en) 2020-03-31
CA2939892A1 (fr) 2015-09-24
JP6152489B2 (ja) 2017-06-21
EA030159B1 (ru) 2018-06-29
US10301309B2 (en) 2019-05-28
PE20161177A1 (es) 2016-11-18
MY179356A (en) 2020-11-05
US20180105520A1 (en) 2018-04-19
MA39750A (fr) 2017-01-25

Similar Documents

Publication Publication Date Title
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA35576B1 (fr) Nouveaux composés
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA41562A1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA38483A1 (fr) Inhibiteurs de l'ido
MA37888B1 (fr) Composition pharmaceutique enrobée contenant du régorafenib
MA42397B1 (fr) 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA35444B1 (fr) Ligands du récepteur ep1
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA49127B1 (fr) Dérivés d'indole n-substitués
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA39750B1 (fr) Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA40149A1 (fr) Dérivés de nucléoside 4'-vinyle substitués utiles en tant qu'inhibiteurs de la réplication due l'arn du virus respiratoire syncytial
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
MA39253B1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr